Hiroshi Tanabe

11PUBLICATIONS
87CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 17, 2026
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

|Aug 07, 2026
Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026).

|Jul 30, 2026
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

|Feb 07, 2026
Long-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies.

Chikage Narui, Hiroshi Tanabe, Masataka Takenaka

|Apr 05, 2024
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer.

Hiromi Komazaki, Kazuaki Takahashi, Hiroshi Tanabe

Pageof 2

Frequent Collaborators

10 joint publications

Aikou Okamoto

5 joint publications

Hirokuni Takano

3 joint publications

Suguru Odajima

3 joint publications

Kyosuke Yamada